Company Overview
Upexi, Inc. engages in the development, manufacture, and distribution of a diverse range of consumer products, specifically offering nail grinders and healthy all-natural pet supplements under the LuckyTail brand, energy solutions under the PRAX brand, functional mushrooms under the Cure Mushrooms brand, and cannabinoids under the Moon brand. The company operates within the Communication Services sector and the Internet Content & Information industry, positioning itself as a provider of specialized goods that leverage digital distribution channels or content-driven models typical of this classification. The organization employs a workforce of 59 individuals to support its product lines and operational infrastructure. With a market capitalization of $69.34M and annual revenue of $24.74M, Upexi represents a small-cap entity with a relatively modest scale in the broader financial landscape. These valuation figures indicate that the company is a micro-cap stock with limited resources and a niche market presence, where the revenue base is just under $25 million, suggesting a business that is still in a scaling phase or operating within a specific, perhaps fragmented, market segment rather than a dominant industry leader.
Financial Health
The company reported revenue of $24.74M for the trailing twelve months, yet it recorded a net income of $-122,934,128 and an EBITDA of $-114,581,064, revealing a significant structural disconnect where operating expenses vastly exceed gross profits. This massive gap between revenue and net income indicates a highly leveraged cost structure or substantial one-time charges, as the operating margin stands at -2160.2% while the profit margin is listed at 0.0%, suggesting that the reported net income figure is so negative relative to revenue that the standard percentage metric becomes mathematically negligible or zero in reporting. The free cash flow stands at $-216,210,592, which signifies a severe lack of financial flexibility, as the company is burning cash at a rate that exceeds its total debt obligations on a quarterly basis. Regarding liquidity and leverage, the company holds $1.62M in cash against $213.48M in total debt, resulting in a debt-to-equity ratio of 438.20, which characterizes the balance sheet as extremely aggressive and highly leveraged rather than conservative. Despite the high debt load, the current ratio is 2.20, indicating that the company technically possesses enough current assets to cover its current liabilities, though this liquidity buffer is precarious given the continuous cash burn. Furthermore, the return on equity is -468.5% and the return on assets is -49.9%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate negative returns. The gross margin remains robust at 80.7%, implying that the core products have strong pricing power or low cost of goods sold, but this strength is entirely negated by the overwhelming operating and interest expenses that drive the overall profitability into deep negative territory.
Valuation Assessment
The trailing P/E ratio is N/A due to the absence of net income, while the forward P/E is listed as -3.51, a negative figure that implies the market is pricing in a continued period of negative earnings or is utilizing a different metric framework for future expectations. The price-to-book ratio is 1.29, indicating that the market values the company at a 29% premium over its book value, which is an unusual valuation for a company with such significant losses and negative earnings power. The price-to-sales ratio stands at 2.80 and the EV/EBITDA is -2.46, suggesting that investors are valuing the company primarily on its top-line revenue growth potential rather than its current profitability or cash generation capabilities. The stock has a 52-week high of $22.57 and a 52-week low of $0.54, meaning the current trading price sits in a highly volatile range relative to its recent history, having experienced a massive expansion from the low end. The beta value is -0.35, which indicates an inverse correlation to the broader market, meaning the stock tends to move in the opposite direction of the market index, adding a unique layer of idiosyncratic risk and volatility to the investment profile. These valuation metrics collectively suggest that the market is willing to pay a premium for the business model despite the lack of traditional profitability, likely betting on a turnaround or a specific niche advantage that is not yet reflected in the earnings statements.
Growth & Income
The revenue growth year-over-year is 101.0%, while the earnings growth year-over-year is N/A due to the company's negative earnings, indicating that the top line is expanding rapidly while profitability remains nonexistent. The company is not a dividend payer, as the dividend yield is N/A and the payout ratio is 0.0%, which means the company reinvests all available resources, including its negative earnings and cash reserves, into growth initiatives or debt servicing rather than distributing income to shareholders. Given the massive negative free cash flow and the lack of dividends, the overall growth and income profile is defined by aggressive expansion in revenue accompanied by a significant cash burn that must be managed carefully to avoid liquidity crises before the business achieves sustained profitability.